ADMA Biologics (NASDAQ:ADMA) Stock Price Down 2.9% – Time to Sell?

ADMA Biologics, Inc. (NASDAQ:ADMA) shares traded down 2.9% during trading on Friday . The stock traded as low as $16.51 and last traded at $16.52. 2,053,399 shares were traded during mid-day trading, a decline of 43% from the average session volume of 3,579,065 shares. The stock had previously closed at $17.01.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ADMA. Mizuho boosted their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, June 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, HC Wainwright increased their price objective on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, August 12th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $15.50.

ADMA Biologics Stock Performance

The stock has a market capitalization of $3.97 billion, a P/E ratio of -857.25 and a beta of 0.62. The company’s fifty day simple moving average is $17.72 and its 200 day simple moving average is $12.32. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. The company had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm’s quarterly revenue was up 78.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.02) earnings per share. As a group, sell-side analysts forecast that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Insider Transactions at ADMA Biologics

In related news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Young Kwon sold 60,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now owns 241,441 shares in the company, valued at $4,408,712.66. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Quest Partners LLC purchased a new position in shares of ADMA Biologics in the second quarter worth $29,000. EntryPoint Capital LLC bought a new position in shares of ADMA Biologics during the first quarter valued at about $31,000. CWM LLC boosted its holdings in shares of ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares during the period. Acadian Asset Management LLC bought a new stake in shares of ADMA Biologics in the second quarter worth about $93,000. Finally, Viewpoint Capital Management LLC grew its stake in shares of ADMA Biologics by 18.6% in the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 2,416 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.